Results 161 to 170 of about 20,886 (213)

Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM. [PDF]

Eur Cardiol
Hasegawa K, Iguchi M, Wada H, Dan GA.
europepmc   +1 more source

Troponin: biology, molecular mechanisms, and multidimensional clinical applications. [PDF]

Mol Biomed
Adamcova M, Petráň L.
europepmc   +1 more source

Cardiac myosin inhibitors in hypertrophic cardiomyopathy: gaps in knowledge and future opportunities

Shanghai Chest
Mehran Rahimi, Monica Ahluwalia, Ralf Martz Sulague, Jacques Kpodonu   +3 more
openaire   +1 more source

Reduced Plasma Cardiac Myosin-Binding Protein-C Concentrations in Cats with Hypertrophic Cardiomyopathy: Evidence from Chronic, Treated Disease. [PDF]

Animals (Basel)
Tanakwang N, Sakunasing N, Kumphune S, Mektrirat R, Na Lampang K, Boonyapakorn C, Pongkan W.   +6 more
europepmc   +1 more source

Probing relaxed myosin states in hypertrophic cardiomyopathy by second harmonic-generation microscopy. [PDF]

Elife
Arecchi G, Dente M, Ma W, Scellini B, Piroddi N, Scardigli M, Yu J, Zhao J, Cicchi R, Kinegawa R, Muellenbroich C, Sera F, Poggesi C, Ferrantini C, Irving TC, Regnier M, Sacconi L, Tesi C.   +17 more
europepmc   +1 more source

Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with <i>RAF1</i>-associated Noonan syndrome-case report. [PDF]

Eur Heart J Case Rep
Seghers HM, Ectors B, Alaerts M, Saenen J, Van Craenenbroeck EM.   +4 more
europepmc   +1 more source

Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies. [PDF]

Front Cardiovasc Med
Chen NK, Hok KD, Chokshi N, Shadid A, Rich HE, Gunamalai L, Doursout MF, Banda NK, Shivshankar P.   +8 more
europepmc   +1 more source

Epigenetic and chromatin remodeling mechanisms across cardiomyopathies: a comprehensive review. [PDF]

Epigenetics Chromatin
Upadhyaya P.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

FDA Approves First Cardiac Myosin Inhibitor

Nature Reviews Drug Discovery, 2022
Asher Mullard
exaly   +2 more sources

First-in-Class Cardiac Myosin Inhibitor Reduces Symptoms of HCM

Nature Reviews Cardiology, 2020
Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
Gregory B Lim
exaly   +3 more sources